Sarissa Capital Management LP's Q3 2026 13F: 1 position resized, no new positions or exits
Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 16, 2026 · 10 reported positions · accession 0001420506-26-002892
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Reduced | AMARIN CORP PLC (AMRN) | 15.0% | 10.9% | −4.1 pts | −386K sh | −23% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
No changes in the top 10 this quarter
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | INNOVIVA INC (INVA) | 24.1% | 26.2% | |
| 2 | IRONWOOD PHARMACEUTICALS INC (IRWD) | 21.7% | 23.8% | |
| 3 | AMARIN CORP PLC (AMRN) | 15.0% | 10.9% | |
| 4 | LANTHEUS HLDGS INC (LNTH) | 10.4% | 10.8% | |
| 5 | NEUROCRINE BIOSCIENCES INC (NBIX) | 11.0% | 10.8% | |
| 6 | CYTOKINETICS INC (CYTK) | 10.9% | 9.8% | |
| 7 | BIOHAVEN LTD (BHVN) | 4.9% | 5.1% | |
| 8 | REGENERON PHARMACEUTICALS (REGN) | 1.5% | 2.1% | |
| 9 | VOR BIOPHARMA INC (VOR) | 0.3% | 0.3% | |
| 10 | BIOGEN INC (BIIB) | 0.1% | 0.1% |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).